Scientific Sessions

AHA CEO: Driving breakthroughs

AHA CEO describes how to continue to deliver on the AHA mission during its second century.

Wake-up call: Heeding global risk factors

Daily 231112 Lf Aha 006

Scientific Sessions 2024 Daily News coverage

Health Tech winners

AI medical company wins global health tech competition at #AHA24

241116 American Heart Association Keynote 0080

LBS 08: Advances in lipid therapeutics

Crowd shot

LBS 07: New approaches to managing AFib

Combined linear ablation, radiofrequency ablation, metformin and aggressive risk factor management.

Stage shot

LBS 06: Medical therapy for heart failure

Myeloperoxidase inhibitor, Sacubitril-Valsartan, standard loop diuretic and sodium zirconium cyclosilicate and spironolactone.

Screening for Kidney Disease to Reduce CVD Risk

Screening for Kidney Disease to Reduce CVD Risk

uACR and eGFR testing are the first step.

Stage shot

LBS 05: Innovation in prevention

Two-drug polypills, electronic nudges, ZODIAC and pacemakers.

Managing patients with symptomatic mitral or tricuspid regurgitation

Discussion explores the role M-TEER and T-TEER play.

Shot of speakers

Environmental crises call for more CV research

Pollution, rising temperatures can have a big impact on health.

Screening for Kidney Disease to Reduce CVD Risk

Screening for Kidney Disease to Reduce CVD Risk

Unmet Needs in Hypertension Toolkit

Unmet Needs in Hypertension Toolkit

Lp(a) and Peripheral Artery Disease Toolkit

Lp(a) and Peripheral Artery Disease Toolkit

CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management

CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management

Aha24 Nejm Web Image

Streamlining the pathway to publish cardiovascular research

Starting in 2025, research authors will have the option to select a seamless transfer of their manuscript between NEJM and Circulation.

Dissecting the complex relationship between atrial cardiomyopathy and stroke

Paul Dudley White Lecture lays groundwork for promising patient outcomes.

Stage shot

LBS 04: Coronary and valvular heart disease

Liberal or restrictive oxygenation, GLP-1 agonist therapy, edoxaban and spironolactone.

Stage shot

LBS 03: Harnessing AI for better heart health

Improving guideline-directed medical therapy, comparing wearable versus implanted sensors, boosting echocardiogram performance and automating echocardiographic interpretation.

Tweets by AHAScience

Headshots of speakers

Improving patient outcomes for sudden cardiac arrest

audience shot

LBS 02: Redefining arrhythmia treatment

Headshots of speakers

At the intersection of heart and brain

From left: Alviar, Dahiya and Proudfoot

Collaborating across the Atlantic on critical care cardiology

Fudim

Early Career Investigator Showcase illuminates paths forward in research

Streur

Nurses drive programs, clinics to treat heart disease

From left: Adedinsewo, Mieres and Coutinho

What women want: Better cardiovascular health

Ah Atv Webimage

Watch AHAtv

2024 Distinguished Scientists Base

AHA selects six Distinguished Scientists for 2024

Shah Silvi Base

Q&A: Research Goes Red recognition

Alexander Adigun

Challenged by rare cardiomyopathies

Patrono Base

Aspirin's staying power